About Daniel Graifman
Form D filings for Thylacine Biotherapeutics in 2023 list Daniel Graifman as executive officer and director.
Daniel Graifman first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name Daniel Graifman in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Daniel Graifman works with at each company, as listed on that company's latest Form D.
Thylacine Biotherapeutics Inc · Form D, Jan 19, 2023
RG
Robert Graifman
Director
AF
Andrew Fradkin
Secretary and General Counsel, director